Navigation Links
Peregrine in Medical Technology

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the...

New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models

-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established Tumors in a Preclinical Breast Cancer Model -- -- R84 Is Being ...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, the human antibody therapeutics company announced today that Peregrine Pharmaceuticals, Inc. reported positive in vivo test results of R3, a fully human monoclonal antibody developed by Affitech, in a pancreatic cancer model at the recently...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... TUSTIN, Calif., June 3 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today high... posted at www.peregrineinc.com . About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

... TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today annou...nced solid cancers is also continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

...TUSTIN, Calif., April 22 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical...hia (PA): AACR; 2009. Abstract nr 5463 About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

...TUSTIN, Calif., April 21 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinica... Medical Center in Dallas, a scientific advisor to peregrine and co-author of one of the AACR presentations. "...f preclinical studies by a team of scientists from peregrine Pharmaceuticals and Affitech A/S used a fully huma...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

...TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), today ann...d solid cancers is also continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial

...tion Criteria in Solid Tumors (RECIST) criteria. peregrine president and CEO, Steven W. King noted, "We are v...advanced solid cancers is also continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

... - peregrine Achieves Milestone as Third Phase II Trial in Its ...CH) and Good Clinical Practices (GCP) standards. peregrine recently reported that a Phase II trial assessing ...advanced solid cancers is also continuing. About peregrine Pharmaceuticals ...

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer

...l in advanced solid cancers is continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...lead product candidates bavituximab and Cotara(R). peregrine also has in- house manufacturing capabilities thro...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

...l in advanced solid cancers is continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...lead product candidates bavituximab and Cotara(R). peregrine also has in-house manufacturing capabilities throu...

Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio

...ti-aminophospholipid agents. The new patents grant peregrine broad anti-viral method claims using a range of ph...r substances. "These are significant patents for peregrine that substantially expand our intellectual propert...at the breadth of the issued claims, which provide peregrine with U.S. patent coverage for methods of combating...

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...unday, June 1, 2008 2:00 PM - 6:00 PM CDT. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...lead product candidates bavituximab and Cotara(R). peregrine also has in-house manufacturing capabilities throu...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... in patients co-infected with HCV and HIV. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab

...lead author Dr. Monica Friedrich and colleagues at peregrine show that both bavituximab and PGN635 cause the de...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... that enhances innate anti-tumor immune responses, peregrine Pharmaceuticals, Inc., April 15, 2008, 8:00 AM - 1...

Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... TX, April 14, 2008, 1:00 PM - 4:00 PM PDT About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ...ted in part by a sponsored research agreement with peregrine Pharmaceuticals and by a grant from the U.S. Depar...las, TX, April 14, 2008, 2:10 PM - 2:25 PM About peregrine Pharmaceuticals ...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... TX, April 14, 2008, 8:00 AM -12:00 PM PDT About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents

...se stabilization in 50% of the evaluable patients. peregrine recently received regulatory approval to conduct t...t the Hyatt Regency Hotel in La Jolla, CA. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct two ad...in patients co- infected with HCV and HIV. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

... -- peregrine Has Now Received Regulatory Approval for Three Pha...se stabilization in 50% of the evaluable patients. peregrine has now received regulatory approval for three Pha... in patients co-infected with HCV and HIV. About peregrine Pharmaceuticals ...

Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

...se stabilization in 50% of the evaluable patients. peregrine has filed three Phase II cancer protocols to study... in patients co-infected with HCV and HIV. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV

...tible to the development of anti-viral resistance. peregrine has completed two bavituximab Phase I monotherapy ...trials for the treatment of solid cancers. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer

...ter ended July 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Cont...

Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV

...tible to the development of anti-viral resistance. peregrine has completed two bavituximab Phase l monotherapy ...h encouraging signs of anti-viral activity. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer

...ar ended April 30, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Cont...

Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

...as supported by the U.S. Army Medical Research and Materiel Command under W81XWH-06-1-0050 (DOD PC05031 grant) and a sponsored research agreement with peregrine Pharmaceuticals, Inc. Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregri...

Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors

...as supported by the U.S. Army Medical Research and Materiel Command under W81XWH-06-1-0050 (DOD PC05031 grant) and a sponsored research agreement with peregrine Pharmaceuticals, Inc. Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregri...

Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

...half of its victims within 14 months of diagnosis. peregrine believes that combined positive data from this new...a by the U.S. Food and Drug Administration. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

..., Calif., April 16, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. a clinical stage biopharmace...ted in part by a sponsored research agreement with peregrine Pharmaceuticals. The fully human antibody R3 used ...dical Ctr., Dallas, TX, Affitech AS, Oslo, Norway, peregrine Pharmaceuticals Inc., Tustin, CA, UT-MD Anderson, ...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

..., Calif., April 17, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. , a clinical stage biopharma...ted in part by a sponsored research agreement with peregrine Pharmaceuticals and by a grant from the U.S. Depar...allas, TX, Apr 16, 2007, 1:00 PM - 5:00 PM About peregrine Pharmaceuticals ...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

..., Calif., April 18, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. , a clinical stage biopharma..., TX, Apr 17, 2007, 8:00 AM - 12:00 PM EDT About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

..., Calif., April 18, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. , a clinical stage biopharma...or virus infections including chronic hepatitis C, peregrine also intends to assess the utility of the new clas...r the Cure and a sponsored research agreement with peregrine Pharmaceuticals Inc. Number 3539: Inhibition of ...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

... programs reinforce our belief that the future for peregrine has never been brighter, and we look forward to pr...ted Anti-PS Antibody Researchers affiliated with peregrine presented a number of preclinical studies demonstr...r development programs. Researchers working with peregrine presented data on progress in the company's VTA co...

Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients

...d in combination with chemotherapy or radiation. peregrine intends to present more complete data from this tr...priate scientific meeting later this year. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...
Other Tags
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
(Date:6/2/2015)... 2015 Thermi, formerly ThermiAesthetics, a ... successfully transitioned into its new company headquarters in ... company’s continued rapid worldwide expansion and houses the ... 25 Thermi employees, including those of the warehousing, ... “As one of the fastest growing aesthetic companies ...
(Date:6/2/2015)... June 02, 2015 Atlantic Spine ... spine surgery with three locations in New Jersey, announces ... City. The new facility is at 1045 Park Avenue ... consultations and appointments can be arranged by calling 1-844-912-2406. ... at Atlantic Spine Center, has been a pioneer in ...
(Date:6/2/2015)... Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... publisher of audit, compliance and risk solutions ... a new online risk management effectiveness gap-improvement program. ... the effect of uncertainty on objectives. Organizations not ... they improve their capabilities to do this (risk ...
(Date:6/1/2015)... 02, 2015 The National Association ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in life coaching. NAPW is ... boasting more than 700,000 members and over 200 operating ... with this distinction,” said NAPW President Star Jones. “Her ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Everette-Gaines as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in business. ... for professional women, boasting more than 700,000 members ... pleased to welcome Kathy into this exceptional group ...
Breaking Medicine News(10 mins):Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2
Other Contents